drugset / Trial / NCT00288249

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

NCT00288249

Phase 2 Completed 82 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with metastatic breast cancer

Timeline

Start
2005-12
Primary completion
2008-03
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sagopilone Small molecule 12 mg/m2 Intravenous
Subject Sagopilone Small molecule 16 mg/m2 Intravenous
Subject Sagopilone Small molecule 22 mg/m2 Intravenous

Indications